Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018) (2018)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1001/jamacardio.2018.0612
- Subjects: FÁRMACOS; INFARTO DO MIOCÁRDIO; ESTUDOS RANDOMIZADOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Jama cardiology
- ISSN: 2380-6583
- Volume/Número/Paginação/Ano: v. 3, n. 5, p. 445-445, 2018
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
BERWANGER, O. e NICOLAU, J. C. e CARVALHO, A. C. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018). Jama cardiology, v. 3, n. 5, p. 445-445, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamacardio.2018.0612. Acesso em: 04 out. 2024. -
APA
Berwanger, O., Nicolau, J. C., & Carvalho, A. C. (2018). Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018). Jama cardiology, 3( 5), 445-445. doi:10.1001/jamacardio.2018.0612 -
NLM
Berwanger O, Nicolau JC, Carvalho AC. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018) [Internet]. Jama cardiology. 2018 ; 3( 5): 445-445.[citado 2024 out. 04 ] Available from: https://doi.org/10.1001/jamacardio.2018.0612 -
Vancouver
Berwanger O, Nicolau JC, Carvalho AC. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018) [Internet]. Jama cardiology. 2018 ; 3( 5): 445-445.[citado 2024 out. 04 ] Available from: https://doi.org/10.1001/jamacardio.2018.0612 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Anticoagulação e antiagregação plaquetária nas síndromes isquêmicas miocárdicas instáveis [Carta]
Informações sobre o DOI: 10.1001/jamacardio.2018.0612 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
